RT期刊文章SR电子T1试行的肉毒杆菌毒素和职业治疗作家的抽筋(p4.8 - 019)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p4.8补充92 - 019签证官是15 A1荣格大肠公园A1埃贾兹·、正在首页A1 Pattamon Panyakaew A1卡米洛·托罗A1乔纳森Sackett A1一生马修A1芭芭拉·卡普A1 Codrin Lungu A1凯瑟琳改变A1莫妮卡安妮Faye Villegas A1天下吴A1奥马尔·艾哈迈德A1 Sungyoung Auh A1马克哈雷特年2019 UL //www.ez-admanager.com/content/92/15_supplement/p4.8 - 019. -文摘AB目的:我们的目的是比较肉毒杆菌毒素的影响(肉毒毒素)单独治疗结合肉毒毒素和职业治疗患者作家的痉挛患者自我评分主观尺度来衡量。背景:作家的抽筋(WC)是一种局部肌张力障碍,当前最好的焦肉毒毒素注射治疗。过去的研究表明,某些类型的康复治疗可能是有用的。我们推测,肉毒毒素和职业治疗会比单独肉毒毒素治疗WC的病人。设计/方法:十二WC病人被随机分为两组。6只有肉毒毒素治疗和6收到肉毒毒素治疗和职业治疗。所涉及的职业疗法的具体练习手指运动方向相反的病人的矛盾的运动在写作任务。主要结果是患者自我评分主观量表在20周。次要结果评估四个失明video-raters使用几个尺度(作者的痉挛评定量表:WCRS,作家的抽筋障碍:组织,和作者的抽筋残疾量表:WCDS)。结果:患者自我评分主观量表得分在20周两治疗组之间没有显著差异。重复测量方差分析显示,有一个显著的相互作用时间(访问1和访问8)和组(肉毒毒素和肉毒毒素+ OT)为组织和WCRS (P < 0.05)。减少组织(从25 - 18)被发现显著的提升装置+ OT组。其他次要结果措施(WCDS、手柄和螺旋错误),没有显著差异。Conclusions: The patient-rated subjective scale scores at 20 weeks were not significantly different between the two groups. However, WCIS scores were significantly improved with combination therapy compared with BoNT alone. Our study findings are limited by a small sample size. Therefore, further study of occupational therapy methods to improve the efficacy of BoNT seem worthwhile.Disclosure: Dr. Park has nothing to disclose. Dr. Shamim has received research support from Kaiser Permanente MidAtlantic Permanente Medical Group. Dr. Panyakaew has nothing to disclose. Dr. Toro has received research support from National Institutes of Health. Dr. Sackett has nothing to disclose. Dr. Mathew has nothing to disclose. Dr. Karp has received research support from Allergan and Merz Neuroscience. Dr. Lungu has nothing to disclose. Dr. Alter has nothing to disclose. Dr. Villegas has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Ahmad has nothing to disclose. Dr. Auh has nothing to disclose. Dr. Hallett has received personal compensation in an editorial capacity for Elsevier. Dr. Hallett has received royalty, license fees, or contractual rights payments from Brainsway via the NIH. Dr. Hallett has received research support from Allergan, Medtronic, Inc., and CALA Health.